Literature DB >> 28283879

Ovarian cancer epidemiology in the era of collaborative team science.

Rikki A Cannioto1, Britton Trabert2, Elizabeth M Poole3, Joellen M Schildkraut4.   

Abstract

PURPOSE: Over the past decade, a number of consortia have formed to further investigate genetic associations, pathogenesis, and epidemiologic risk and prognostic factors for ovarian cancer. Here, we review the benefits that ovarian cancer consortia provide as well as challenges that have arisen. Methods for managing key challenges are also discussed.
METHODS: We review the structural organization and some of the milestone epidemiologic publications of five consortia dedicated to the study of ovarian cancer, including the Ovarian Cancer Association Consortium (OCAC), the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Ovarian Cancer Cohort Consortium (OC3), the Collaborative Group on Epidemiological Studies of Ovarian Cancer (The Oxford Collaborative Group), and the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
RESULTS: As ovarian cancer is a rare and heterogeneous disease, consortia have made important contributions in the study of risk factors by improving statistical power beyond what any single study, or even a few studies, would provide. Thus, a major accomplishment of consortial research is enhanced characterization of histotype-specific risk factor associations. In addition, consortia have facilitated impressive synergy between researchers across many institutions, spawning new collaborative research. Importantly, through these efforts, many challenges have been met, including difficulties with data harmonization and analysis, laying a road map for future collaborations.
CONCLUSIONS: While ovarian cancer consortia have made valuable contributions to the ovarian cancer epidemiological literature over the past decade, additional efforts comprising of new, well-designed case-control studies are needed to further elucidate novel, histotype-specific risk, and prognostic factors which are not consistently available in existing studies.

Entities:  

Keywords:  Consortium; Epidemiology; Ovarian cancer

Mesh:

Year:  2017        PMID: 28283879      PMCID: PMC5616164          DOI: 10.1007/s10552-017-0862-6

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  42 in total

1.  The evolution of epidemiologic research: from cottage industry to "big" science.

Authors:  Robert N Hoover
Journal:  Epidemiology       Date:  2007-01       Impact factor: 4.822

2.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

3.  Invited commentary: consolidating data harmonization--how to obtain quality and applicability?

Authors:  Isabel Fortier; Dany Doiron; Paul Burton; Parminder Raina
Journal:  Am J Epidemiol       Date:  2011-07-11       Impact factor: 4.897

4.  SEARCH programme of the International Agency of Research on Cancer.

Authors:  P Boyle
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Honglin Song; Susan J Ramus; Maria Notaridou; Kate Lawrenson; Martin Widschwendter; Robert A Vierkant; Melissa C Larson; Susanne K Kjaer; Michael J Birrer; Andrew Berchuck; Joellen Schildkraut; Ian Tomlinson; Lambertus A Kiemeney; Linda S Cook; Jacek Gronwald; Montserrat Garcia-Closas; Martin E Gore; Ian Campbell; Alice S Whittemore; Rebecca Sutphen; Catherine Phelan; Hoda Anton-Culver; Celeste Leigh Pearce; Diether Lambrechts; Mary Anne Rossing; Jenny Chang-Claude; Kirsten B Moysich; Marc T Goodman; Thilo Dörk; Heli Nevanlinna; Roberta B Ness; Thorunn Rafnar; Claus Hogdall; Estrid Hogdall; Brooke L Fridley; Julie M Cunningham; Weiva Sieh; Valerie McGuire; Andrew K Godwin; Daniel W Cramer; Dena Hernandez; Douglas Levine; Karen Lu; Edwin S Iversen; Rachel T Palmieri; Richard Houlston; Anne M van Altena; Katja K H Aben; Leon F A G Massuger; Angela Brooks-Wilson; Linda E Kelemen; Nhu D Le; Anna Jakubowska; Jan Lubinski; Krzysztof Medrek; Anne Stafford; Douglas F Easton; Jonathan Tyrer; Kelly L Bolton; Patricia Harrington; Diana Eccles; Ann Chen; Ashley N Molina; Barbara N Davila; Hector Arango; Ya-Yu Tsai; Zhihua Chen; Harvey A Risch; John McLaughlin; Steven A Narod; Argyrios Ziogas; Wendy Brewster; Aleksandra Gentry-Maharaj; Usha Menon; Anna H Wu; Daniel O Stram; Malcolm C Pike; Jonathan Beesley; Penelope M Webb; Xiaoqing Chen; Arif B Ekici; Falk C Thiel; Matthias W Beckmann; Hannah Yang; Nicolas Wentzensen; Jolanta Lissowska; Peter A Fasching; Evelyn Despierre; Frederic Amant; Ignace Vergote; Jennifer Doherty; Rebecca Hein; Shan Wang-Gohrke; Galina Lurie; Michael E Carney; Pamela J Thompson; Ingo Runnebaum; Peter Hillemanns; Matthias Dürst; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Ralf Butzow; Tuomas Heikkinen; Kari Stefansson; Patrick Sulem; Sören Besenbacher; Thomas A Sellers; Simon A Gayther; Paul D P Pharoah
Journal:  Nat Genet       Date:  2010-09-19       Impact factor: 38.330

6.  Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.

Authors:  Merlise A Clyde; Rachel Palmieri Weber; Edwin S Iversen; Elizabeth M Poole; Jennifer A Doherty; Marc T Goodman; Roberta B Ness; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Nicolas Wentzensen; Alice S Whittemore; Hoda Anton-Culver; Elisa V Bandera; Andrew Berchuck; Michael E Carney; Daniel W Cramer; Julie M Cunningham; Kara L Cushing-Haugen; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Galina Lurie; Valerie McGuire; Francesmary Modugno; Kirsten B Moysich; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Joseph H Rothstein; Thomas A Sellers; Weiva Sieh; Daniel Stram; Pamela J Thompson; Robert A Vierkant; Kristine G Wicklund; Anna H Wu; Argyrios Ziogas; Shelley S Tworoger; Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2016-10-03       Impact factor: 4.897

7.  Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Lindsay M Morton; Joshua N Sampson; James R Cerhan; Jennifer J Turner; Claire M Vajdic; Sophia S Wang; Karin E Smedby; Silvia de Sanjosé; Alain Monnereau; Yolanda Benavente; Paige M Bracci; Brian C H Chiu; Christine F Skibola; Yawei Zhang; Sam M Mbulaiteye; Michael Spriggs; Dennis Robinson; Aaron D Norman; Eleanor V Kane; John J Spinelli; Jennifer L Kelly; Carlo La Vecchia; Luigino Dal Maso; Marc Maynadié; Marshall E Kadin; Pierluigi Cocco; Adele Seniori Costantini; Christina A Clarke; Eve Roman; Lucia Miligi; Joanne S Colt; Sonja I Berndt; Andrea Mannetje; Anneclaire J de Roos; Anne Kricker; Alexandra Nieters; Silvia Franceschi; Mads Melbye; Paolo Boffetta; Jacqueline Clavel; Martha S Linet; Dennis D Weisenburger; Susan L Slager
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

8.  Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Authors:  Kathryn L Terry; Stalo Karageorgi; Yurii B Shvetsov; Melissa A Merritt; Galina Lurie; Pamela J Thompson; Michael E Carney; Rachel Palmieri Weber; Lucy Akushevich; Wei-Hsuan Lo-Ciganic; Kara Cushing-Haugen; Weiva Sieh; Kirsten Moysich; Jennifer A Doherty; Christina M Nagle; Andrew Berchuck; Celeste L Pearce; Malcolm Pike; Roberta B Ness; Penelope M Webb; Mary Anne Rossing; Joellen Schildkraut; Harvey Risch; Marc T Goodman
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-12

9.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

Authors:  Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore
Journal:  Int J Epidemiol       Date:  2013-04       Impact factor: 7.196

10.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 11.816

View more
  11 in total

Review 1.  Association between Cigarette Smoking and Histotype-Specific Epithelial Ovarian Cancer: A Review of Epidemiologic Studies.

Authors:  Aili Zhou; Albina N Minlikeeva; Sadat Khan; Kirsten B Moysich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-01       Impact factor: 4.254

2.  Histotype classification of ovarian carcinoma: A comparison of approaches.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Michael Anglesio; Kristine Wicklund; Rex Bentley; Andrew Berchuck; Linda E Kelemen; Tayyebeh M Nazeran; C Blake Gilks; Holly R Harris; David G Huntsman; Joellen M Schildkraut; Mary Anne Rossing; Martin Köbel; Jennifer A Doherty
Journal:  Gynecol Oncol       Date:  2018-08-16       Impact factor: 5.482

3.  High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Authors:  Katharine K Brieger; Minh Tung Phung; Bhramar Mukherjee; Kelly M Bakulski; Hoda Anton-Culver; Elisa V Bandera; David D L Bowtell; Daniel W Cramer; Anna DeFazio; Jennifer A Doherty; Sian Fereday; Renée Turzanski Fortner; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Holly R Harris; Keitaro Matsuo; Usha Menon; Francesmary Modugno; Kirsten B Moysich; Bo Qin; Susan J Ramus; Harvey A Risch; Mary Anne Rossing; Joellen M Schildkraut; Britton Trabert; Robert A Vierkant; Stacey J Winham; Nicolas Wentzensen; Anna H Wu; Argyrios Ziogas; Lilah Khoja; Kathleen R Cho; Karen McLean; Jean Richardson; Bronwyn Grout; Anne Chase; Cindy McKinnon Deurloo; Kunle Odunsi; Brad H Nelson; James D Brenton; Kathryn L Terry; Paul D P Pharoah; Andrew Berchuck; Gillian E Hanley; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-17       Impact factor: 4.090

4.  Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.

Authors:  Lilah Khoja; Rachel Palmieri Weber; Penelope M Webb; Susan J Jordan; Aruna Muthukumar; Jenny Chang-Claude; Renée T Fortner; Allan Jensen; Susanne K Kjaer; Harvey Risch; Jennifer Anne Doherty; Holly R Harris; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Andrew Berchuck; Joellen M Schildkraut; Daniel Cramer; Kathryn L Terry; Hoda Anton-Culver; Argyrios Ziogas; Minh Tung Phung; Gillian E Hanley; Anna H Wu; Bhramar Mukherjee; Karen McLean; Kathleen Cho; Malcolm C Pike; Celeste Leigh Pearce; Alice W Lee
Journal:  Gynecol Oncol       Date:  2021-11-12       Impact factor: 5.304

5.  Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Martin Köbel; Holly R Harris; Andrew Berchuck; Mary Anne Rossing; Joellen M Schildkraut; Jennifer A Doherty
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

6.  Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

Authors:  Jennifer Anne Doherty; Lauren Cole Peres; Chen Wang; Gregory P Way; Casey S Greene; Joellen M Schildkraut
Journal:  Curr Epidemiol Rep       Date:  2017-07-10

7.  Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Authors:  Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

8.  Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Authors:  Ellen L Goode; Matthew S Block; Kimberly R Kalli; Robert A Vierkant; Wenqian Chen; Zachary C Fogarty; Aleksandra Gentry-Maharaj; Aleksandra Tołoczko; Alexander Hein; Aliecia L Bouligny; Allan Jensen; Ana Osorio; Andreas Hartkopf; Andy Ryan; Anita Chudecka-Głaz; Anthony M Magliocco; Arndt Hartmann; Audrey Y Jung; Bo Gao; Brenda Y Hernandez; Brooke L Fridley; Bryan M McCauley; Catherine J Kennedy; Chen Wang; Chloe Karpinskyj; Christiani B de Sousa; Daniel G Tiezzi; David L Wachter; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gregg Nelson; Jan Lubiński; Janusz Menkiszak; Jennifer Alsop; Jenny Lester; Jesús García-Donas; Jill Nation; José Palacios; Joseph H Rothstein; Joseph L Kelley; Jurandyr M de Andrade; Luis Robles-Díaz; Maria P Intermaggio; Martin Widschwendter; Matthias W Beckmann; Matthias Ruebner; Mercedes Jimenez-Linan; Naveena Singh; Oleg Oszurek; Paul R Harnett; Peter F Rambau; Peter Sinn; Philipp Wagner; Prafull Ghatage; Raghwa Sharma; Robert P Edwards; Roberta B Ness; Sandra Orsulic; Sara Y Brucker; Sharon E Johnatty; Teri A Longacre; Eilber Ursula; Valerie McGuire; Weiva Sieh; Yanina Natanzon; Zheng Li; Alice S Whittemore; deFazio Anna; Annette Staebler; Beth Y Karlan; Blake Gilks; David D Bowtell; Estrid Høgdall; Francisco J Candido dos Reis; Helen Steed; Ian G Campbell; Jacek Gronwald; Javier Benítez; Jennifer M Koziak; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; María José García; Peter A Fasching; Stefan Kommoss; Suha Deen; Susanne K Kjaer; Usha Menon; James D Brenton; Paul DP Pharoah; Georgia Chenevix-Trench; David G Huntsman; Stacey J Winham; Martin Köbel; Susan J Ramus
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 33.006

9.  Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Authors:  Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

10.  Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p.

Authors:  Changhong Wang; Shan Qi; Cheng Xie; Chunfu Li; Pu Wang; Dongmei Liu
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.